Extreme Movers: Gemini 1.5 Pro's picks for 2026-09-09
Gemini 1.5 Pro picked ROIV, SMR, SEI, DYN, FCEL for a 1-day horizon. Average directional return: -1.90%. Directions called correctly: 40%.
| Experiment | Extreme Movers |
|---|---|
| Model | Gemini 1.5 Pro |
| Prompt version | extreme-movers-v6 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-09-08 |
| Measured to | 2026-09-09 |
| Benchmark | SPY |
| Status | Settled |
| Average directional return | -1.90% |
| Directions called correctly | 40% |
| Benchmark return | -0.46% |
The picks
| Rank | Symbol | Direction | Price change | Return in the called direction | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|---|---|
| 1 | ROIV | up | +0.80% | +0.80% | 80% | +1.26% | Yes |
| 2 | SMR | up | -3.31% | -3.31% | 75% | -2.84% | No |
| 3 | SEI | down | +5.80% | -5.80% | 70% | -5.34% | No |
| 4 | DYN | down | -5.51% | +5.51% | 75% | +5.98% | Yes |
| 5 | FCEL | up | -6.70% | -6.70% | 65% | -6.24% | No |
The model's market view
Following the September 8, 2026 session, market sentiment remains heavily polarized. Clean energy, nuclear, and specific clinical-stage biotech stocks experienced aggressive speculative momentum, driving massive top-gainer surges. Conversely, firms facing sudden fundamental scrutiny or earnings disappointments saw sharp downside momentum. Positioning into the September 9 session focuses heavily on whether these high-beta extreme movers can sustain their momentum or succumb to mean-reverting profit-taking.
Why each pick
ROIV
Roivant Sciences surged 17.38% on September 8 following positive Phase 2 clinical trial results for mosliciguat and subsequent price target hikes from major Wall Street firms like Citi. The catalyst is substantive, backed by clinical data and analyst target increases. Given the strong institutional backing and high relative volume, momentum is expected to continue upward in the next session.
SMR
NuScale Power jumped 15.21% on September 8 amid heightened investor optimism for advanced small modular nuclear reactor technology tailored for AI data-center energy demands. The catalyst is a mix of speculative enthusiasm and growing structural interest in nuclear power infrastructure. Strong volume and retail momentum favor a continuation of the upward trend.
SEI
Solaris Energy Infrastructure gained 16.07% on September 8 as traders reacted to capital deployment and debt structure developments supporting energy infrastructure buildouts. The catalyst is substantive, reflecting fundamental sector demand. However, after such an aggressive single-session expansion, the risk of a minor intraday pullback or consolidation makes a mean-reversion hypothesis plausible.
DYN
Dyne Therapeutics plummeted 16.35% on September 8 following an upsized public stock offering and clinical setbacks that triggered heavy selling pressure. The catalyst is substantive and highly dilutive. With intense downward momentum established and institutional distribution underway, the bearish continuation trend is expected to persist into the next session.
FCEL
FuelCell Energy faced sharp scrutiny and increased selling pressure related to its recent financial disclosures and Q3 gross loss disclosures concerning its Fit Energy agreement, leading to a steep decline. The fundamental headwinds are substantive, but the stock's high short interest and extreme volatility open the door for a short-term relief bounce or mean-reverting recovery.
Other models on the same run
| Model | Picks | Average directional return | Directions called correctly |
|---|---|---|---|
| GPT-5.6 Sol | ROIV, BSX, LITE, BE, AMGN | +0.43% | 60% |
| Muse Spark 1.1 | CBRS, SNDK, IONQ, GME, CEG | -2.61% | 20% |
| Grok 4.5 | INTC, AMGN, ROIV, FCEL, SEI | +0.41% | 80% |
| Gemini 3 Pro | ROIV, SMR, CRWV, INTC, GPRO | -0.59% | 60% |
| Claude Opus 5 | FCX, AMD, SRPT, QCOM, SYK | -0.34% | 40% |
Written up on ForecastNest Insights: Extreme Movers: Gemini 1.5 Pro's picks for 2026-09-09.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.